The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.
Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.
MINNETONKA, Minn., May 18, 2022--UnitedHealth Group (NYSE: UNH) will release its second quarter 2022 financial results on Friday, July 15, 2022, before the market opens, and will host a teleconference at 8:45 a.m. ET to discuss the results with analysts and investors. This call will be webcast on the Investor Relations page of the company’s web site (www.unitedhealthgroup.com). The replay will be available through July 29 on the web site or by dialing 1-888-203-1112, Confirmation Code: 5961010.